Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Infergen + Ribavirin in HCV Nonresponders (IRHC-002)
NCT00162734Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Feb 2005
- Primary completion
- Jun 2007
- Modality
- PEGylated Peptides, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of Peginterferon alfacon-1 in hepatitis C (HCV) (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Sustained Virologic Response at 72 weeks. Started Feb 2005; status: completed.
02
Drugs
Peginterferon alfacon-1
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00162734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00162734.